Labetalol Pediatric Dose — Cardiovascular Infusions
Labetalol is a combined alpha- and beta-adrenergic receptor antagonist that reduces systemic vascular resistance and cardiac output, producing a controlled reduction in blood pressure. It is used in pediatric patients for the management of acute hypertension and hypertensive urgency or emergency requiring a continuous intravenous infusion. Its dual mechanism makes it particularly useful when both vasodilation and heart rate control are desired.
Pediatric Dosing
For continuous intravenous infusion, the recommended dose range is 0.4–1 mg/kg/hr, titrated to effect. The maximum infusion rate is 3 mg/kg/hr.
- Starting infusion: 0.4 mg/kg/hr IV
- Titration range: 0.4–1 mg/kg/hr IV
- Maximum rate: 3 mg/kg/hr IV
Worked example — 20 kg child: Starting dose: 20 × 0.4 mg/kg/hr = 8 mg/hr; target range up to 20 × 1 mg/kg/hr = 20 mg/hr; absolute maximum 20 × 3 mg/kg/hr = 60 mg/hr. Consult institutional protocol for specific titration intervals and concentration preparation.
Indications and Clinical Context
Labetalol continuous infusion is indicated for pediatric patients requiring sustained blood pressure reduction in the setting of hypertensive urgency or emergency, such as hypertensive encephalopathy, acute glomerulonephritis, or post-operative hypertension in the PICU setting. Its titratable intravenous formulation allows for precise blood pressure management in monitored environments.
As a cardiovascular infusion agent, labetalol is appropriate when a gradual, controlled reduction in blood pressure is preferred over intermittent bolus dosing. Standard pediatric hypertension guidelines recommend targeting no more than a 25% reduction in mean arterial pressure within the first 8 hours of treatment to avoid end-organ hypoperfusion; consult institutional or current evidence-based protocols for specific targets.
Administration and Monitoring
Labetalol should be administered as a continuous intravenous infusion via a dedicated or compatible IV line, ideally through a central venous catheter in critically ill patients, though peripheral administration is used in some settings. Continuous cardiorespiratory monitoring is essential, including heart rate, blood pressure (ideally via arterial line in the PICU), and oxygen saturation.
- Monitor for bradycardia and heart block; labetalol’s beta-blockade effect may suppress compensatory tachycardia.
- Use with caution or avoid in patients with reactive airway disease, decompensated heart failure, or hemodynamically significant bradycardia.
- Monitor blood glucose in neonates and infants, as beta-blockade may mask hypoglycemia symptoms.
- Maximum infusion rate: 3 mg/kg/hr; do not exceed without specialist guidance.
- Consult institutional protocol for admixture concentration and compatible diluents.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.